Galena Biopharma (GALE +7.7%) jumps this morning after Aegis Capital initiated the shares with a Buy and a $6.00 price target. Aegis says that GALE has developed a novel approach to combating the recurrence of breast cancer in patients with minimal residual disease. The firm's lead candidate, NeuVax, is a peptide vaccine derived from a protein that is the target of several widely used breast cancer treatments. It's currently conducting Phase III trials and is slated to report interim data in late 2013.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at CNBC.com (May 21, 2014)
at CNBC.com (Apr 8, 2014)
at CNBC.com (Mar 17, 2014)
at MarketWatch.com (Mar 17, 2014)
at CNBC.com (Jan 16, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs